Compare AstraZeneca plc (AZN) vs PPG Industries, Inc. (PPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs PPG Industries, Inc. — how do they compare? AstraZeneca plc trades at $157.95 (market cap $248.14B), while PPG Industries, Inc. trades at $116.16 (market cap $25.82B). The key difference: AstraZeneca plc is far larger — about 9.6× PPG Industries, Inc.'s market cap, and PPG Industries, Inc. pays the higher dividend (2.55%). Which is the better fit depends on your goals.
| AZN | PPG | |
|---|---|---|
Market Cap | $248.14B | $25.82B |
Sector | Health | Basic Materials |
52-Week High | $209.48 | $131.56 |
52-Week Low | $147.06 | $94.34 |
Enterprise Value | $275.41B | $31.69B |
Dividend Yield | 2.01% | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
PPG Industries trades at $115.47, down 3.55% amid bearish technical signals, though fundamentals show resilience with Q2 2026 sales up 7% year-over-year and a 4.2% dividend hike in July 2026. The stock's valuation appears reasonable with a P/E of 16.67 and P/S of 1.59, while profitability metrics like a 9.57% net margin and 19.63% ROE support operational strength. Recent leadership changes in Industrial Coatings and FTSE4Good recognition highlight ongoing corporate developments.
Wall Street maintains a bullish stance with 55% buy ratings and a $129.17 consensus target, implying 12% upside, but near-term risks include raw material cost pressures and mixed earnings performance. The technical bearish signal and proximity to support at $114 suggest cautious entry points, while the dividend aristocrat status and solid cash flow provide downside protection for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →
